Recommendations Against Methylprednisolone in Acute Cervical Spinal Cord Injury

Guideline Consensus

Lack of Neurological Benefit

Harm Profile

Recommended Acute Management (Alternatives to Steroids)

Clinical Practice Implications

Corticosteroid Use in Acute Spinal Cord Injury: Evidence‑Based Recommendations

Guideline Consensus Against Steroid Administration

• The 2020 French spinal‑cord‑injury guidelines issue a GRADE 1 (strong) recommendation against early methylprednisolone administration for improving neurological prognosis after acute traumatic spinal cord injury. 3
• The 2013 Congress of Neurological Surgeons (CNS) downgraded the evidence for methylprednisolone from Class I to Class III, stating that all primary outcomes in the NASCIS trials were negative and any reported benefits derived from post‑hoc subgroup analyses. 4
• The 2017 AO Spine guidelines provide a weak, optional suggestion to offer a 24‑hour high‑dose methylprednisolone infusion within 8 hours of injury, based on modest subgroup findings from NASCIS II; this suggestion conflicts with later stronger recommendations. 3

Lack of Neurological Benefit Demonstrated in Trials

• NASCIS I compared two methylprednisolone dosing regimens (1 g vs 100 mg) and found no difference in neurological improvement; the study lacked a placebo control, making efficacy conclusions impossible. 4
• NASCIS II reported a modest motor‑score improvement at 6 months only in a post‑hoc subgroup of patients treated within 8 hours; this was not a pre‑specified primary endpoint. 3
• NASCIS III compared 24‑hour versus 48‑hour methylprednisolone infusions and demonstrated no additional motor improvement with the longer regimen. 4
• A large Canadian propensity‑score‑matched cohort (≈ 1,600 control patients and 46 patients receiving methylprednisolone) showed no improvement in one‑year motor function after adjustment for injury level and baseline severity. 3

Significant Harm Associated with Steroid Use

• Infectious complications were higher in steroid‑treated patients: NASCIS II reported a 7 % infection rate versus 3 % in the placebo group. 3

Proven Alternative Interventions (Supported by Guidelines)

• Immediate transfer of patients to a specialized spinal‑cord‑injury center carries a GRADE 2+ recommendation and is associated with reduced morbidity and long‑term mortality compared with care at non‑specialized facilities. 3
• Early magnetic‑resonance imaging (MRI) when neurological deficits are not explained by computed tomography helps identify compressive lesions (e.g., hematoma, disc herniation) that may require urgent surgical decompression. This practice is endorsed by the same guideline bodies. 3

Bottom line: High‑quality guideline bodies (French Society, CNS, AO Spine) and multiple high‑level studies consistently demonstrate that methylprednisolone provides no meaningful neurological benefit and increases infection risk in acute spinal‑cord injury. Consequently, its routine use is not recommended, and clinicians should prioritize rapid transfer to specialized centers and early diagnostic imaging to improve outcomes.